dabigatran has been researched along with Atherogenesis in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Broncel, M; Gorzelak-Pabiś, P; Pawlos, A; Wojdan, K; Woźniak, E | 1 |
| Ali, H; Balla, C; Bonitta, G; Briani, M; Cappato, R; Chiarito, M; Furlanello, F; Giustozzi, M; Lodigiani, C; Lupo, P; Riva, L; Stefanini, G | 1 |
| Guo, JQ; Ji, JJ; Ma, GS; Qian, LL; Wu, YP; Yao, YY | 1 |
| Bauwens, M; Brandenburg, V; Briedé, JJ; Bröker, V; Bucerius, J; Dijkgraaf, I; Dweck, MR; Jennen, D; Leenders, P; Mottaghy, F; Reutelingsperger, CP; Schurgers, LJ; Spronk, HMH; van Gorp, RH; van Ryn, J | 1 |
| Cuccia, C; Enea, I; Fresco, C; Paciaroni, M; Patti, G; Pecora, D; Rocca, B; Rubboli, A | 1 |
| Chevalier, P; Chinezu, L; Dobreanu, D; Fișcă, PC; Gheban, D; Gherțescu, D; Huțanu, A; Mărginean, A; Perian, M; Scridon, A; Șerban, RC; Vântu, A | 1 |
| Feldmann, K; Fender, AC; Fischer, JW; Gerfer, S; Grandoch, M; Hartwig, S; Kohlmorgen, C; Lehr, S; Nagy, N; Valentin, B | 1 |
| Biessen, EA; Borissoff, JI; Daemen, MJ; Degen, JL; Esmon, CT; Hackeng, TM; Hamulyák, K; Heeneman, S; Leenders, P; Loubele, ST; Otten, JJ; Soehnlein, O; Spronk, HM; ten Cate, H; van Oerle, R; van Ryn, J; Weiler, H | 1 |
| Esmon, CT | 1 |
| Bea, F; Cabbage, S; Ieronimakis, N; Preusch, MR; Reyes, M; Ricks, J; Rosenfeld, ME; van Ryn, J; Wijelath, ES | 1 |
| Kadoglou, NP; Kapelouzou, A; Katsimpoulas, M; Kostakis, A; Kostomitsopoulos, N; Liapis, CD; Moustardas, P; Schafer, K | 1 |
| Alegret, M; Laguna, JC | 1 |
1 review(s) available for dabigatran and Atherogenesis
| Article | Year |
|---|---|
Targeting factor Xa and thrombin: impact on coagulation and beyond.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Atherosclerosis; Benzimidazoles; Blood Coagulation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Evaluation, Preclinical; Factor Xa; Humans; Inflammation; Pyrazoles; Pyridines; Pyridones; Receptors, Proteinase-Activated; Thrombin; Thrombosis | 2014 |
11 other study(ies) available for dabigatran and Atherogenesis
| Article | Year |
|---|---|
Expression of anti and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: A comparison of rivaroxaban and dabigatran.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Cytokines; Dabigatran; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxycholesterols; Interleukin-18; Interleukin-23; Oxysterols; Rivaroxaban; RNA, Messenger; Transforming Growth Factor beta | 2022 |
Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Stroke; Warfarin | 2021 |
Protective role of serpina3c as a novel thrombin inhibitor against atherosclerosis in mice.
Topics: Animals; Antithrombins; Aorta; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Dabigatran; Diet, High-Fat; Male; Mice, Inbred C57BL; Mice, Knockout; Neointima; Plaque, Atherosclerotic; Serpins; Signal Transduction; Thrombin | 2021 |
Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate.
Topics: Animals; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Female; Humans; Mice; Vitamin K; Warfarin | 2021 |
How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Italy; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Surveys and Questionnaires; Thiazoles; Thrombosis; Treatment Outcome | 2021 |
Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration - results from a diabetes animal model.
Topics: Animals; Antithrombins; Aorta; Atherosclerosis; Coronary Vessels; Dabigatran; Diabetes Mellitus, Experimental; Drug Administration Schedule; Lipid Metabolism; Male; Plaque, Atherosclerotic; Platelet Aggregation; Rats, Wistar; Receptors, Thrombin; Time Factors; Up-Regulation | 2019 |
Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation.
Topics: Adipose Tissue; Animals; Antithrombins; Aorta, Thoracic; Atherosclerosis; Dabigatran; Disease Models, Animal; Female; Flow Cytometry; Immunohistochemistry; Inflammation; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout | 2019 |
Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Blood Coagulation; Dabigatran; Disease Models, Animal; Disease Progression; Female; Hematopoiesis; Inflammation; Mice; Mice, Knockout; Neutrophils; Phenotype; Plaque, Atherosclerotic; Pyridines; Reactive Oxygen Species; Thrombin; Thrombosis | 2013 |
Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.
Topics: Age Factors; Animals; Antithrombins; Apolipoproteins E; Atherosclerosis; Dabigatran; Disease Models, Animal; Disease Progression; Flow Cytometry; Leukocyte Common Antigens; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oncostatin M; Sinus of Valsalva | 2015 |
The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice : dabigatran etexilate and atherosclerosis.
Topics: Animals; Antithrombins; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Dabigatran; Male; Matrix Metalloproteinase 9; Mice; Mice, Knockout; NF-kappa B; Pyridines; Tissue Inhibitor of Metalloproteinase-1; Vascular Cell Adhesion Molecule-1 | 2012 |
Dabigatran etexilate: another double-edged drug? : editorial to: "the beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice" by N. Kadoglou e
Topics: Animals; Antithrombins; Atherosclerosis; Benzimidazoles; Dabigatran; Male; Mice; Pyridines | 2012 |